BriaCell Therapeutics Corp. (BCT) will present results from clinical studies with its lead product candidate, Bria-IMT™ at the 2021 AACR Meeting.
The American Association for Cancer Research (AACR) Annual Meeting is held over two weeks, from April 10 to 15 and May 17 to the 21.
The findings indicate disease control in advanced breast cancer patients, including stable disease, partial responses or complete responses.
Disease control was especially noted in patients with Grade I/II tumours or those that matched Bria-IMT™ at 2 or more HLA alleles.
Patients with low or undetectable levels of circulating cancer cells were more likely to benefit from therapy.
Patients were treated with the Bria-IMT™ regimen alone or the Bria-IMT™ regimen combined with immune checkpoint inhibitors, including pembrolizumab and, more recently, Incyte’s retifanlimab.
Dr. Bill Williams, BriaCell’s President & CEO, presented the clinical and pathological analysis results. The patient data summarized and discussed belong to previously disclosed patients.
The Bria-IMT™ regimen with or without checkpoint inhibitors can induce an effective immune response and disease control in heavily pre-treated advanced breast cancer patients.
The patients were all heavily pretreated and failed multiple prior regimens.
Patients with Grade I/II tumours (median of 8 prior therapy regimens) were more likely to respond with the disease control (67 per cent) and longer progression-free survival.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
BriaCell Therapeutics Corp. (BCT) is down 26.25 per cent and is trading at C$4.72 at 2:07 pm ET.